Ionis Q3 2023 revenue $144M, net loss $143M; eplontersen on track for Dec 2023 U.S. approval

IONIS PHARMACEUTICALS INC

2023-Q3 EPS reported -$2.50 revenue$463,142,000

Total revenue $144M (-10% YoY); SPINRAZA royalties $67M flat; R&D revenue $60M down from $87M.
Operating expenses $287M (+31% YoY); loss from operations $143M vs. $59M loss in Q3 2022.
Cash and short-term investments $2.2B; reaffirmed 2023 financial guidance.
Eplontersen regulatory submissions accepted in EU and Canada; potential U.S. approval in Dec 2023.
Olezarsen Phase 3 Balance study met endpoints: significant triglyceride lowering, reduced pancreatitis attacks; on track for early 2024 filings.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.99

IONIS PHARMACEUTICALS INC updated its the third quarter of 2023 guidance (reaffirmed).

Period: the third quarter of 2023
Guidance: reaffirmed
Result: reported results

Exact text from the filing

today reported financial results for the third quarter of 2023.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

IONIS PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001140361-23-051047

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.